UCLA study reveals bone-building protein’s impact on bone stem cells

  • UCLA study shows that administering the protein NELL-1 intravenously causes bone stem cells to stimulate significant bone formation.
  • Results from the study show that NELL-1 has dual effects on the two different cell populations that are in charge of either forming bone or breaking it down.
  • These results could one day have substantial impact on the development of a treatment for bone loss, including osteoporosis.

Study maps prenatal cells

Research delivers new data for stem cell scientists to more accurately study infertility

Brain Research Funded

Research could one day aid the development of treatments for neurological diseases such as autism, Alzheimer’s disease, Parkinson’s disease, and others

New cellular link uncovered


Study sheds light on cell signaling pathways that influence birth defects, disease

Stem Cell Patent Announced

Patented method important step in validating stem cell research

Lowry Plath

UCLA stem cell scientists go out on a limb for motor neuron disease

Research could lead to better understanding of diseases such as ALS

Bennett Novitch, Ph.D.

UCLA research shows promising method for correcting genetic code to treat sickle cell disease

UCLA researcher pioneers gene therapy cure for ‘Bubble Baby’ disease

UCLA stem cell researchers have pioneered a stem cell gene therapy cure for children born with a life-threatening condition called adenosine deaminase–deficient severe combined immunodeficiency, or ADA-deficient SCID. Often called Bubble Baby disease, the condition can be fatal within two years if left untreated.

The groundbreaking treatment was developed by Dr. Donald Kohn, a renowned stem cell researcher and member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

UCLA and UCI awarded $8m grant to launch collaborative stem cell clinic “center of excellence”

Promising results in stem cell trial for blindness

Dr. Steven Schwartz of the UCLA Jules Stein Eye Institute and Broad Stem Cell Research Center, his colleagues, and the sponsor, Advanced Cell Technology (ACT), announced the successful results of the first human embryonic stem cell (hESC) derived cell transplant clinical trial approved by the FDA to complete a clinical trial.